Status of O6 -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India

Neurology India

Volumn 60, Issue 5, 2012, Pages 481-486

  Nehru, Gopal Arun ^a   Pai, Rekha ^a   Samuel, Prasanna ^a   Chacko, Ari George ^a   Chacko, Geeta ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Bisulfite sequencing; glioblastoma multiforme; methylation specific PCR; O 6 methylguanine DNA methyltransferase

Indexed keywords

BISULFITE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; CANCER RECURRENCE; CANCER TISSUE; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INDIA; METHYLATION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROMOTER REGION;

ADOLESCENT; AGED; BRAIN NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; INDIA; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84869995038     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.103190     Document Type: Article

References (33)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K. A distinct region of the MGMT CpGisland critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. ActaNeuropathol 2011;121:651-61.
3. Gorlia T, Van Den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9:29-38.
4. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
5. Etcheverry A, Aubry M, De Tayrac M, Vauleon E, Boniface R, Guenot F, et al. DNA methylation in glioblastoma: Impact on gene expression and clinical outcome. BMC Genomics 2010;11:701.
6. Stupp R, Hegi ME. Methylguaninemethyltransferase testing in glioblastoma: When and how? J ClinOncol 2007;25:1459-60.
7. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, et al. Comprehensive analysis of MGMT promoter methylation: Correlation with MGMT expression and clinical response in GBM. PLoS One 2011;6:e16146.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
9. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: Proposal of a feasible immunohistochemical approach. ActaNeuropathol 2008;115:249-59.
10. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: Results from the CCG-945 Cohort. J Clin Oncol 2006;24:3431-7.
11. Jha P, Suri V, Jain A, Sharma MC, Pathak P, Srivastava A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: First Indian report with review of challenges for use in customized treatment. Neurosurgery 2010;67:1681-91.
12. Srivastava A, Jain A, Jha P, Suri V, Sharma MC, Mallick S, et al. MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst 2010;26:1613-8.
13. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
14. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
15. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
16. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J MolDiagn 2007;9:368-81.
17. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007;121:2458-64.
18. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990;50:6119-29.
19. Qian XC, Brent TP. Methylation hot spots in the 5'OElig; flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 1997;57:3672-7.
20. Weller M, Stupp R, Reifenberger G, Brandes AA, Van Den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol 2009;6:39-51.
21. Von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2010;21:74-87.
22. Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumors: Systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer 2011;11:35.
23. Preusser M, Charles JR, Felsberg J, Reifenberg G, Hamou MF, Diserens AC, et al. Anti O6-Methylguanine-DNA methyltransferase (MGMT) immunohistochemistry in glioblastomamultiforme: Observor variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008;18:520-32.
24. Karayan-Tapon L, Quillen V, Guilhot J, Wager M, Fromont G, Sailali S, et al. Prognostic of O6-Methylguanine-DNA methyltransferase status in glioblastoma patients assessed by five different methods. J Neurooncol 2010;97:311-22.
25. Preusser M. MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 2009;24:511-8.
26. Yachi K, Watanabe T, Ohta T, Fukushima T, Yoshino A, Ogino A, et al. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 2008;33:469-75.
27. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-85.
28. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 2007;87:392-7.
29. Hilton DA, Penney M, Pobereskin L, Sanders H, Love S. Histological indicators of prognosis in glioblastomas: Retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology 2004;44:555-60.
30. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006;65:846-54.
31. Salvati M, Formichella AI, D'Elia A, Brogna C, Frati A, Giangaspero F, et al. Cerebral glioblastoma with oligodendrogliomal component: Analysis of 36 cases. J Neurooncol 2009;94:129-34.
32. Pinto LW, Araujo MB, Vettore AL, Wernersbach L, Leite AC, Chimelli L, et al. Glioblastomas: Correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch 2008;452:481-90.
33. Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, Schrock E. Glioblastomas with oligodendroglial component - common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst) 2010;33:37-54.